Last reviewed · How we verify
Measles Vaccine (MV)
Measles Vaccine (MV) is a Live attenuated vaccine Biologic drug developed by PATH. It is currently FDA-approved for Prevention of measles in children and adults, Post-exposure prophylaxis in unvaccinated or susceptible individuals.
The measles vaccine stimulates the immune system to produce antibodies and cellular immunity against the measles virus, preventing infection and disease.
The measles vaccine stimulates the immune system to produce antibodies and cellular immunity against the measles virus, preventing infection and disease. Used for Prevention of measles in children and adults, Post-exposure prophylaxis in unvaccinated or susceptible individuals.
At a glance
| Generic name | Measles Vaccine (MV) |
|---|---|
| Sponsor | PATH |
| Drug class | Live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains live attenuated (weakened) measles virus that replicates in the body without causing disease, triggering both humoral (antibody) and cell-mediated immune responses. This primes the immune system to recognize and rapidly neutralize wild-type measles virus upon exposure, providing long-lasting protection against measles infection.
Approved indications
- Prevention of measles in children and adults
- Post-exposure prophylaxis in unvaccinated or susceptible individuals
Common side effects
- Fever
- Rash
- Local injection site reactions (pain, erythema, swelling)
- Lymphadenopathy
- Thrombocytopenia (rare)
Key clinical trials
- The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age (PHASE4)
- A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer (PHASE1)
- A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001) (PHASE1)
- Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery (PHASE1)
- Vaccine Campaign Effects on General Hospital Admissions and Mortality Among Children (PHASE4)
- A Second Dose of Measles Vaccine (MV) in the Second Year of Life (NA)
- Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006) (PHASE2)
- Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Measles Vaccine (MV) CI brief — competitive landscape report
- Measles Vaccine (MV) updates RSS · CI watch RSS
- PATH portfolio CI
Frequently asked questions about Measles Vaccine (MV)
What is Measles Vaccine (MV)?
How does Measles Vaccine (MV) work?
What is Measles Vaccine (MV) used for?
Who makes Measles Vaccine (MV)?
What drug class is Measles Vaccine (MV) in?
What development phase is Measles Vaccine (MV) in?
What are the side effects of Measles Vaccine (MV)?
Related
- Drug class: All Live attenuated vaccine drugs
- Manufacturer: PATH — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of measles in children and adults
- Indication: Drugs for Post-exposure prophylaxis in unvaccinated or susceptible individuals
- Compare: Measles Vaccine (MV) vs similar drugs
- Pricing: Measles Vaccine (MV) cost, discount & access